Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart procedure put to the test in patients over 80

NCT ID NCT07403760

Symptom relief Sponsor: Beijing Anzhen Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times

Summary

This study looks at whether a procedure called catheter ablation can improve quality of life for people aged 80 and older who have a heart rhythm problem called atrial fibrillation. Half of the 182 participants will get the real procedure, and half will get a fake one (sham) to see if the real one truly helps. The main goal is to see if the procedure leads to better daily wellbeing after 6 months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 136 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

80 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥ 80 years. 2. Documented paroxysmal or persistent atrial fibrillation by ECG or Holter within 6 months prior to enrollment. 3. Symptomatic AF (including palpitations, chest tightness, fatigue, dizziness, blackouts, dyspnea). 4. Voluntary participation and signed informed consent. Exclusion Criteria: 1. NYHA Class IV heart failure. 2. Acute myocardial infarction, cardiac surgery, or PCI within the past 1 year. 3. Long-standing persistent AF (duration \> 1 year). 4. Left atrial anteroposterior diameter \> 6 cm. 5. History of prior AF ablation. 6. AF secondary to reversible causes (e.g., post-surgery, infection, hyperthyroidism). 7. Severe mitral stenosis. 8. Moderate to severe hepatic failure (Child-Pugh B-C). 9. Renal failure stage 4-5 (eGFR \<30 ml/min/1.73m2) or continuous dialysis. 10. Inability to cooperate due to dementia or severe mental disorder. 11. Presence of left atrial thrombus. 12. Prior Left Atrial Appendage Occlusion (LAAO). 13. Contraindication to anticoagulation. 14. Life expectancy \< 1 year.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial fibrillation (AF) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrial fibrillation (AF)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Beijing Anzhen Hospital, Capital Medical University, Beijing, China

    RECRUITING

    Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.